Credit Suisse’s Edgewise Therapeutics EWTX Stock Holding History

Credit Suisse’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$368K	Buy	20,166 +2,867	+17%	+$45.6K	﹤0.01%	2760
2023 Q4	$189K	Buy	+17,299	New	+$121K	﹤0.01%	2996
2023 Q1	–	Sell	-1	Closed	-$9	–	3419
2022 Q4	$9	Sell	1 -194	-99%	-$1.82K	﹤0.01%	3749
2022 Q3	$2K	Buy	195 +159	+442%	+$1.61K	﹤0.01%	3719
2022 Q2	$0	Buy	+36	New	+$272	﹤0.01%	4037
2021 Q4	–	Sell	-98,395	Closed	-$1.63M	–	4550
2021 Q3	$1.63M	Sell	98,395 -112,773	-53%	-$2.04M	﹤0.01%	2966
2021 Q2	$4.5M	Buy	211,168 +127,116	+151%	+$3.47M	﹤0.01%	2176
2021 Q1	$2.73M	Buy	+84,052	New	+$2.73M	﹤0.01%	2579

Other funds holding EWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Credit Suisse's EWTX Position: Q1 2024 in Review

Credit Suisse increased its Edgewise Therapeutics (EWTX) stake by 17% in Q1 2024, buying an estimated $45.6K and bringing the position to 20,166 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #2760.

Credit Suisse first reported a position in EWTX in Q1 2021 and has held it in 8 quarters since. The position peaked at $4.5M in Q2 2021. 129 funds tracked by Wall St. Rank hold EWTX as of Q1 2024.

Credit Suisse held 20,166 shares of Edgewise Therapeutics worth $368K as of Q1 2024.
Credit Suisse bought 2,867 Edgewise Therapeutics shares in Q1 2024, an estimated $45.6K.
Edgewise Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2760 holding.
Credit Suisse first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 8 quarters since.
Credit Suisse's Edgewise Therapeutics position peaked at $4.5M in Q2 2021.
129 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.